Adrian Towse
About
In The Last Decade
Adrian Towse
142 papers receiving 3.2k citations
Peers
Comparison fields: 5 of 162
- Economics and Econometrics 2.4k
- General Health Professions 694
- Pediatrics, Perinatology and Child Health 317
- Immunology 309
- Pharmacology 257
Countries citing papers authored by Adrian Towse
This map shows the geographic impact of Adrian Towse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Towse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Towse more than expected).
Fields of papers citing papers by Adrian Towse
This network shows the impact of papers produced by Adrian Towse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Towse. The network helps show where Adrian Towse may publish in the future.
Co-authorship network of co-authors of Adrian Towse
This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Towse. A scholar is included among the top collaborators of Adrian Towse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Towse. Adrian Towse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 7 | |
| 3 | 1 | |
| 4 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence | 4 |
| 5 | Establishing a Reasonable Price for an Orphan Drug | 1 |
| 6 | What do pharmaceuticals really cost in the long run? | 3 |
| 7 | Four Case Studies to Explore the Added Value of Oxford AHSN | 1 |
| 8 | 14 | |
| 9 | Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. | 47 |
| 10 | International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa | 1 |
| 11 | Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context | 3 |
| 12 | The Market for Biosimilars: Evolution and Policy Options | 12 |
| 13 | Economic Post-Launch Studies: Matching the Desirable with the Feasible | 4 |
| 14 | Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds. Notes on a Conference in Honour of Bernie O’Brien. | 1 |
| 15 | Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. | 24 |
| 16 | 97 | |
| 17 | 29 | |
| 18 | Cost-Effectiveness Thresholds: Economic and ethical issues | 71 |
| 19 | Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty | 14 |
| 20 | Disease Management, the NHS and the Pharmaceutical Industry | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.